Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer: Clinical and Experimental Metastasis

F. Carbone, F. Grossi, A. Bonaventura, A. Vecchié, S. Minetti, N. Bardi, E. Elia, A.M. Ansaldo, D. Ferrara, E. Rijavec, M.G. Dal Bello, F. Biello, G. Rossi, M. Tagliamento, A. Alama, S. Coco, P. Spallarossa, F. Dallegri, C. Genova, F. Montecucco

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)449-456
Number of pages8
JournalClin. Exp. Metastasis
Volume36
Issue number5
DOIs
Publication statusPublished - 2019

Keywords

  • Inflammation
  • Neutrophil
  • Nivolumab
  • Non-small cell lung cancer
  • Osteopontin
  • C reactive protein
  • gamma glutamyltransferase
  • nivolumab
  • osteopontin
  • adult
  • Article
  • cancer survival
  • disease severity
  • enzyme linked immunosorbent assay
  • female
  • follow up
  • gamma glutamyl transferase blood level
  • human
  • hypoalbuminemia
  • immune response
  • liver metastasis
  • lymphocyte count
  • major clinical study
  • male
  • metastasis
  • mortality rate
  • neutrophil count
  • non small cell lung cancer
  • overall survival
  • protein blood level
  • treatment response

Cite this